Revolutionizing Targeted Therapy Trials: Predict Drug Resistance Before It Happens.

Empower your Phase I and II trials with single-cell resolution and quantum-powered analytics—ensuring the right drug for the right patient.

CellaraRx harnesses AI, quantum feature selection, and single-cell RNA sequencing to predict patient response to targeted therapies. Reduce late-stage failures, optimize R&D investments, and pave the way for precision medicine.

Request a Demo

The High Cost of Uncertainty in Phase III Trials

Over half of drugs in Phase III fail due to enrolling patients who ultimately don’t benefit, leading to losses exceeding $100 million per failure.

Traditional methods cannot reliably predict resistance before it’s too late—causing good drugs to fail, wasting resources, and delaying crucial treatments for patients in need.

CellaraRx: Predicting Drug Resistance at the Single-Cell Level

Single-Cell RNA Sequencing: Identifies rare resistant clones that often go undetected.
Quantum Feature Selection: Uses quantum annealing to reveal non-linear gene interactions.
GAN & VAE Modeling: Generates realistic synthetic data for robust predictions.
Actionable Insights: Helps sponsors de-risk Phase III by excluding resistant patients early.

Why Partner with CellaraRx?

Reduce Late-Stage Failures

Identify potential non-responders in Phase II to safeguard precious Phase III resources.

Accelerate Time to Market

Enroll only the right patients for faster proof-of-concept and smoother regulatory pathways.

Enhance Drug Efficacy Profiles

Highlight the best responding subpopulations to show your therapy’s true potential.

Strengthen Market Confidence

Patient selection saves money, earns payer acceptance, and builds trust.

How It Works

1. Sample Collection

Acquire patient tumor samples for single-cell RNA sequencing.

2. Quantum Analysis

Analyze gene interactions with quantum feature selection.

3. Predictive Modeling

Use AI to forecast resistance patterns.

4. Actionable Report

Receive a clear report to guide strategic enrollment.

Proven Impact

80%+

Increase in Phase III Success Probability

$100M+

Saved in Trial Expenses

Faster

Trial Timelines with Smart Enrollment